CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex - Molecular Psychiatry
- ️Tseng, K Y
- ️Tue Mar 04 2014
Andersen SL . Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 2003; 27: 3–18.
Chambers RA, Taylor JR, Potenza MN . Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003; 160: 1041–1052.
Paus T, Keshavan M, Giedd JN . Why do many psychiatric disorders emerge during adolescence? Nat Rev Neurosci 2008; 9: 947–957.
Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117–1127.
Henquet C, Murray R, Linszen D, van Os J . The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005; 31: 608–612.
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007; 370: 319–328.
Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 2012; 109: E2657–E2664.
McGrath J, Welham J, Scott J, Varghese D, Degenhardt L, Hayatbakhsh MR et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry 2010; 67: 440–447.
Kanayama G, Rogowska J, Pope HG, Gruber SA, Yurgelun-Todd DA . Spatial working memory in heavy cannabis users: a functional magnetic resonance imaging study. Psychopharmacology (Berl) 2004; 176: 239–247.
Schweinsburg AD, Brown SA, Tapert SF . The influence of marijuana use on neurocognitive functioning in adolescents. Curr Drug Abuse Rev 2008; 1: 99–111.
Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. Jama 2002; 287: 1123–1131.
Best JR, Miller PH . A developmental perspective on executive function. Child Dev 2010; 81: 1641–1660.
Casey BJ, Giedd JN, Thomas KM . Structural and functional brain development and its relation to cognitive development. Biol Psychol 2000; 54: 241–257.
O'Shea M, Singh ME, McGregor IS, Mallet PE . Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. J Psychopharmacol 2004; 18: 502–508.
Raver SM, Haughwout SP, Keller A . Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice. Neuropsychopharmacology 2013; 38: 2338–2347.
Renard J, Krebs MO, Jay TM, Le Pen G . Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology (Berl) 2013; 225: 781–790.
Schneider M, Koch M . Chronic pubertal, but not adult chronic cannabinoid treatment impairs sensorimotor gating, recognition memory, and the performance in a progressive ratio task in adult rats. Neuropsychopharmacology 2003; 28: 1760–1769.
Schneider M, Schomig E, Leweke FM . Acute and chronic cannabinoid treatment differentially affects recognition memory and social behavior in pubertal and adult rats. Addict Biol 2008; 13: 345–357.
Elsohly MA, Slade D . Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005; 78: 539–548.
Caballero A, Tseng KY . Association of cannabis use during adolescence, prefrontal CB1 receptor signaling, and schizophrenia. Front Pharmacol 2012; 3: 101.
Realini N, Rubino T, Parolaro D . Neurobiological alterations at adult age triggered by adolescent exposure to cannabinoids. Pharmacol Res 2009; 60: 132–138.
Hajos M, Hoffmann WE, Kocsis B . Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: relevance to schizophrenia. Biol Psychiatry 2008; 63: 1075–1083.
Uhlhaas PJ, Linden DE, Singer W, Haenschel C, Lindner M, Maurer K et al. Dysfunctional long-range coordination of neural activity during Gestalt perception in schizophrenia. J Neurosci 2006; 26: 8168–8175.
Uhlhaas PJ, Singer W . Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron 2006; 52: 155–168.
Caballero A, Flores-Barrera E, Cass DK, Tseng KY . Differential regulation of parvalbumin and calretinin interneurons in the prefrontal cortex during adolescence. Brain Struct Funct 2014; 219: 395–406.
Thomases DR, Cass DK, Tseng KY . Periadolescent exposure to the NMDA receptor antagonist MK-801 impairs the functional maturation of local GABAergic circuits in the adult prefrontal cortex. J Neurosci 2013; 33: 26–34.
Cass DK, Thomases DR, Caballero A, Tseng KY . Developmental disruption of gamma-aminobutyric acid function in the medial prefrontal cortex by noncontingent cocaine exposure during early adolescence. Biol Psychiatry 2013; 74: 490–501.
Tagliaferro P, Javier Ramos A, Onaivi ES, Evrard SG, Lujilde J, Brusco A . Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55,212-2. Brain Res 2006; 1085: 163–176.
Wegener N, Koch M . Behavioural disturbances and altered Fos protein expression in adult rats after chronic pubertal cannabinoid treatment. Brain Res 2009; 1253: 81–91.
Paxinos G, Watson C . The Rat Brain in Stereotaxic Coordinates. Academic Press: New York, 1998.
Flores-Barrera E, Thomases DR, Heng LJ, Cass DK, Caballero A, Tseng KY . Late adolescent expression of GluN2B transmission in the prefrontal cortex is input-specific and requires postsynaptic PKA and D1 dopamine receptor signaling. Biol Psychiatry 2014; 75: 508–516.
Heng LJ, Markham JA, Hu XT, Tseng KY . Concurrent upregulation of postsynaptic L-type Ca(2+) channel function and protein kinase A signaling is required for the periadolescent facilitation of Ca(2+) plateau potentials and dopamine D1 receptor modulation in the prefrontal cortex. Neuropharmacology 2011; 60: 953–962.
Becker B, Wagner D, Koester P, Bender K, Kabbasch C, Gouzoulis-Mayfrank E et al. Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study. Psychopharmacology (Berl) 2012; 225: 923–934.
Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berl) 1999; 142: 295–301.
Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR et al. Cannabis use before age 15 and subsequent executive functioning. Br J Psychiatry 2011; 198: 442–447.
Caballero A, Thomases DR, Flores-Barrera E, Cass DK, Tseng KY . Emergence of GABAergic-dependent regulation of input-specific plasticity in the adult rat prefrontal cortex during adolescence. Psychopharmacology (Berl) advance online publication, 2 August 2013; doi:10.1007/s00213-013-3216-4(e-pub ahead of print).
Heng L, Beverley JA, Steiner H, Tseng KY . Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse 2011; 65: 278–286.
Tseng KY, O'Donnell P . Post-pubertal emergence of prefrontal cortical up states induced by D1-NMDA co-activation. Cereb Cortex 2005; 15: 49–57.
Tseng KY, O'Donnell P . Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cereb Cortex 2007; 17: 1235–1240.
Tseng KY, O'Donnell P . D2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex. Synapse 2007; 61: 843–850.
Atakan Z . Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2: 241–254.
Pertwee RG . The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199–215.
Loberg EM, Hugdahl K . Cannabis use and cognition in schizophrenia. Front Hum Neurosci 2009; 3: 53.
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004; 29: 1558–1572.
D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594–608.
Spaderna M, Addy PH, D'Souza DC . Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl) 2013; 228: 525–540.
Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL . “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012; 21: 320–326.
Lovinger DM, Zimmerman SA, Levitin M, Jones MV, Harrison NL . Trichloroethanol potentiates synaptic transmission mediated by gamma-aminobutyric acidA receptors in hippocampal neurons. J Pharmacol Exp Ther 1993; 264: 1097–1103.